Open AccessEffects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double‐blind placebo‐controlled study
Author(s) -
Raftery Tara,
Martineau Adrian R,
Greiller Claire L,
Ghosh Subrata,
McNamara Deirdre,
Bennett Kathleen,
Meddings Jon,
O’Sullivan Maria
Publication year - 2015
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640615572176
Subject(s) - medicine , placebo , gastroenterology , crohn's disease , cathelicidin , calprotectin , vitamin d and neurology , intestinal permeability , colonoscopy , vitamin , randomized controlled trial , inflammatory bowel disease , disease , pathology , colorectal cancer , cancer , innate immune system , alternative medicine , receptor
Background Vitamin D (vitD) supplementation may prolong remission in Crohn's disease (CD); however, the clinical efficacy and mechanisms are unclear. Aim To determine changes in intestinal permeability (IP), antimicrobial peptide (AMP) concentrations and disease markers in CD, in response to vitD supplementation. Methods In a double‐blind randomised placebo‐controlled study, we assigned 27 CD patients in remission to 2000 IU/day vitD or placebo for 3 mos. We determined IP, plasma cathelicidin (LL‐37 in ng/mL), human‐beta‐defensin‐2 (hBD2 in pg/mL), disease activity (Crohn's Disease Activity Index (CDAI)), C‐reactive protein (CRP in mg/L), fecal calprotectin (µg/g), Quality of Life (QoL) and serum 25‐hydroxyvitamin D (25(OH)D in nmol/L) at 0 and 3 mos. Results At 3 mos., 25(OH)D concentrations were significantly higher in those whom were treated ( p < 0.001). Intra‐group analysis showed increased LL‐37 concentrations ( p = 0.050) and maintenance of IP measures in the treated group. In contrast, in the placebo group, the small bowel ( p = 0.018) and gastro‐duodenal permeability ( p = 0.030) increased from baseline. At 3 mos., patients with 25(OH)D ≥ 75 nmol/L had significantly lower CRP ( p = 0.019), higher QoL ( p = 0.037), higher LL‐37 concentrations ( p < 0.001) and non‐significantly lower CDAI scores ( p = 0.082), compared to those with levels <75 nmol/L. Conclusion Short‐term treatment with 2000 IU/day vitD significantly increased 25(OH)D levels in CD patients in remission and it was associated with increased LL‐37 concentrations and maintenance of IP. Achieving 25(OH)D ≥ 75 nmol/l was accompanied by higher circulating LL‐37, higher QoL scores and reduced CRP. Registered at ClinicalTrials.gov (NCT01792388).